
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk […]